



ELSEVIER

European Journal of Heart Failure xx (2007) xxx–xxx

The
European Journal
of
Heart Failure

www.elsevier.com/locate/ejheart

Lung function with carvedilol and bisoprolol in chronic heart failure: Is β selectivity relevant?

Piergiuseppe Agostoni^{a,b,*}, Mauro Contini^a, Gaia Cattadori^a, Anna Apostolo^a,
Susanna Sciomer^c, Maurizio Bussotti^a, Pietro Palermo^a, Cesare Fiorentini^a

^a Centro Cardiologico Monzino, IRCCS, Istituto di Cardiologia, Università di Milano, Milan, Italy

^b Division of Respiratory and Critical Care Medicine, Department of Medicine, University of Washington, Seattle, WA 98185, USA

^c Dipartimento di Scienze Cardiovascolari, Respiratorie e Morfologiche, Università La Sapienza, Roma, Italy

Received 14 December 2006; accepted 26 April 2007

Abstract

Background: Carvedilol is a β -blocker with similar affinity for β_1 - and β_2 receptors, while bisoprolol has higher β_1 affinity. The respiratory system is characterized by β_2 -receptor prevalence. Airway β receptors regulate bronchial tone and alveolar β receptors regulate alveolar fluid re-absorption which influences gas diffusion.

Aims: To compare the effects of carvedilol and bisoprolol on lung function in patients with chronic heart failure (CHF).

Methods and results: We performed a double-blind, cross-over study in 53 CHF patients. After 2 months of full dose treatment with either carvedilol or bisoprolol, we assessed lung function by salbutamol challenge, carbon monoxide lung diffusion (DLCO), including membrane conductance (DM), and gas exchange during exercise. FEV₁ and FVC were similar; after salbutamol FEV₁ was higher with bisoprolol ($p < 0.04$). DLCO was $82 \pm 21\%$ of predicted with carvedilol and $90 \pm 20\%$ with bisoprolol ($p < 0.01$) due to DM changes. Peak VO₂ was 17.8 ± 4.5 mL/min/kg on bisoprolol and 17.0 ± 4.6 on carvedilol, ($p < 0.05$) with no differences in bronchial tone (same expiratory time) throughout exercise. Differences were greater in the 22 subjects with DLCO $< 80\%$.

Conclusion: Carvedilol and bisoprolol have different effects on DLCO and response to salbutamol. DLCO differences, being DM related, are due to changes in active membrane transport which is under alveolar β_2 -receptor control. Peak VO₂ was slightly higher with bisoprolol particularly in CHF patients with reduced DLCO.

© 2007 European Society of Cardiology. All rights reserved.

Keywords: Exercise; Heart failure; Bisoprolol; Carvedilol; Lung diffusion

1. Introduction

Carvedilol and bisoprolol are among the most frequently used β -blocking agents in chronic heart failure (CHF) [1–4]. The two drugs have different pharmacological characteristics, carvedilol has similar affinity for both β_1 and β_2 receptors, whereas bisoprolol has selective affinity (120-

fold) for β_1 vs. β_2 receptors [5]. The respiratory system is characterized by a significant predominance of β_2 receptors, both in the airways and in the alveoli [6,7]. The role of airway β receptors in regulating bronchoconstrictor tone is well-known. However, more than 90% of β receptors in the human lungs are located in the alveoli [7,8], where they regulate fluid re-absorption from the alveolar surface [7], and thereby influence gas exchange efficacy [9,10]. In view of their different β -receptor affinities, it is likely that carvedilol and bisoprolol will have different effects on pulmonary mechanical function and gas diffusion. This is particularly important in CHF, where lung function impairment, both at rest and during exercise, is well known [11–13]. Indeed, in

* Corresponding author. Centro Cardiologico Monzino, IRCCS, Istituto di Cardiologia, Università di Milano, via Parea 4, 20138 Milan, Italy. Tel.: +39 02 58002299; fax: +39 02 58011039.

E-mail address: piergiuseppe.agostoni@ccfm.it (P. Agostoni).

CHF, a restrictive syndrome [11,13], reduction of lung diffusion [11,12,14], bronchial hyper-responsiveness to bronchoconstrictor agents [15], as well as exercise induced hyperventilation [13] and expiratory flow limitation [16,17] have all been described. The present study was undertaken to measure lung function during chronic CHF treatment with carvedilol and bisoprolol. Lung function was evaluated by means of a standard pulmonary function test, both with and without salbutamol challenge, lung diffusion, including lung diffusion subcomponents, membrane diffusion and capillary volume and ventilation behaviour during effort.

2. Methods

2.1. Study population

Patients were recruited from a cohort of consecutive CHF subjects regularly followed at our heart failure unit. Study inclusion criteria were: CHF in NYHA class II–III, stable clinical conditions for at least 2 months, capable of performing a maximal or near-maximal cardiopulmonary exercise test (CPET), previous experience with CPET in our laboratory; and absence of history and/or clinical documentation of pulmonary embolism, primary valvular heart disease, pericardial disease, severe obstructive lung disease, significant peripheral vascular disease, severe anaemia (haemoglobin <11 g/dL), exercise-induced angina, ST-segment changes or severe arrhythmias. The study conforms with the principles outlined in the Declaration of Helsinki and was approved by the local Ethics Committee. All subjects provided written informed consent to participate in the study.

2.2. Quality of life

Quality of life was evaluated by means of the Minnesota Living With Heart Failure Questionnaire [18].

2.3. Echocardiography

Left ventricular volume and ejection fraction were measured in the left lateral decubitus position (Sonos 5500, Andover, MA). Left ventricular volume was derived from the conventional apical 2- and 4-chamber images and the left ventricle ejection fraction was calculated using biplane Simpson's technique. Mitral insufficiency was graded by visual inspection, on a scale of 0 to 4. Pulmonary systolic pressure was estimated by Doppler analysis of the tricuspid leak with right atrial pressure estimation [19].

2.4. Standard pulmonary tests

Standard pulmonary tests were performed according to the American Thoracic Society criteria [20]. Normal predicted values for forced expiratory volume in 1 s (FEV₁) and vital capacity (VC) were those reported by Quajjer et al. [21]. Tests were done before and after salbutamol challenge.

2.5. Lung diffusion

Lung diffusion was measured as lung diffusion for carbon monoxide (DLCO). DLCO was obtained in the standard sitting position with the single breath–constant expiratory flow technique (Sensor Medics 2200, Yorba Linda, CA) [22]. Diffusion subcomponents, DM and capillary volume, were also measured by applying the Roughton and Forster method [23]. For this purpose, subjects inhaled gas mixtures containing 0.3% CH₄ and 0.3% CO, with three different oxygen fractions equal to 20, 40 and 60%, respectively, and balanced with nitrogen. Alveolar volume was measured by CH₄ decay slope during single breath constant expiratory flow measurements [24].

2.6. CPETs

CPETs were done on a cyclo-ergometer (Ergo 800S Sensor Medics, Yorba Linda, CA), using a personalized ramp protocol aimed at achieving peak exercise in 10 min with breath by breath expiratory gases and ventilation analysis (V-Max, Sensor Medics, Yorba Linda, CA) [25]. The test was self-ended by the patients; however, all patients declared that they had performed what they felt to be maximal effort. Anaerobic threshold was measured with the V-slope analysis from the plot of VCO₂ vs. VO₂ on equal scales [26]. The anaerobic threshold value was confirmed by ventilatory equivalents and end-tidal pressures of CO₂ and O₂. The VO₂/work rate relationship was evaluated throughout the entire exercise; the ventilation (V_E)/VCO₂ slope was calculated as the slope of the linear relationship between V_E and VCO₂ from 1 min after the beginning of loaded exercise to the end of the isocapnic buffering period. Two experts read each test independently.

Table 1
Patient characteristics

Number of patients	53
Mean age (years)	63±10
Sex	
Male	48
Female	5
NYHA	
Class II	21
Class III	32
Heart failure aetiology	
Ischaemic cardiomyopathy	22
Dilated cardiomyopathy	31
Cardiac rhythm	
Sinus rhythm	43
Atrial fibrillation	10
Therapy	
diuretics	41
ACE inhibitors	44
AT blockers	8
Digitalis	3
Amiodarone	14
Aldosterone antagonists	30
Antiplatelets/anticoagulants	40

Table shows number of patients unless otherwise indicated.

Table 2

Pulmonary function data in 53 CHF patients during carvedilol and bisoprolol treatment

	Carvedilol	Bisoprolol	<i>p</i>
Vital capacity (L)	3.69±0.89	3.75±0.94	NS
Vital capacity post-salb (L)	3.83±0.93	3.86±0.89	NS
FEV ₁ (L)	2.72±0.76	2.71±0.73	NS
FEV ₁ (L) post-salb (L)	2.71±0.83	2.83±0.73	0.03

CHF=Chronic heart failure; FEV₁=forced expiratory volume at 1 s; salb=salbutamol challenge.

2.7. Study design

The study was a double blind, cross-over design. Both drugs were administered b.i.d. (bis in die). Dose equivalence was 1 (bisoprolol) to 5 (carvedilol) [5] and tablets were 1.25 mg for bisoprolol and 6.25 mg for carvedilol. Patients were randomly assigned to bisoprolol or carvedilol as first treatment. All patients had previously been treated with either carvedilol or bisoprolol; the starting dose used in the study was equivalent to 50% of the dose previously used [5]. For example, if a patient had previously been treated with carvedilol 12.5 mg b.i.d., he could start the study with either carvedilol 6.25 mg b.i.d., or bisoprolol 1.25 mg b.i.d. Thereafter, doses were up-titrated every 2 weeks in order to reach the maximal tolerated dose. The maximal tolerated dose was considered to be the highest dose during which hypotension (systolic blood pressure <90 mm Hg), severe bradycardia (heart rate <44 beat/min during awake rest) or symptoms related to hypotension such as dizziness and fatigue were not observed and/or reported by patients. Once reached, the maximal tolerated dose was maintained for 2 months. On completion of the two month maintenance phase, patients were crossed-over to the other research drug, starting again with a dose equivalent to 50% of that of the previous drug. The effects of bisoprolol and carvedilol on lung function were evaluated at the end of each study period. All patients underwent a standard pulmonary function test including

salbutamol challenge, lung diffusion inclusive of subcomponents, CPET as well as a standard 2D echo-Doppler evaluation.

2.8. Statistical analysis

Data reported are mean±SD. Peak exercise and anaerobic threshold VO₂ measurements are means over 20 s. Differences were analyzed by repeated measurements ANCOVA, adjusting for the timing in the cross-over design. Correlations were analyzed by linear regression analysis. A sample size of 60 patients was calculated in order to assess statistically significant differences between carvedilol and bisoprolol as regards FEV₁ and/or DLCO with a two-tailed alpha value of 0.025, a power of 90%, an expected difference between groups >10% with SD of 20% and a predicted drop-out rate of 10%. A *p* value <0.05 was considered as statistically significant for study parameters other than FEV₁ and DLCO.

3. Results

Sixty CHF patients in a stable clinical condition, who fulfilled the inclusion criteria, were enrolled. Seven patients were lost during the follow-up period, as follows: three revoked their consent to participate in the study, two did not show adequate compliance to therapy, and two were unable to perform pulmonary function tests. Therefore, 53 CHF patients were included in the study. CHF treatment (Table 1) was kept constant throughout the trial.

The mean dose of carvedilol was 27.1±10.0 mg/day and bisoprolol was 4.8±1.8 mg/day. Minnesota Living With Heart Failure Questionnaire scores were 26±20 for carvedilol and for bisoprolol 24±20 (*p*=NS). Echocardiographic measurements were similar for both treatments. Left ventricular systolic volume was 124±54 and 124±55 mL and left ventricle diastolic volume was 196±70 and 196±67 mL, for carvedilol and bisoprolol, respectively. Left ventricular




Fig. 1. From left to right: lung diffusion for carbon monoxide (DLCO), membrane conductance (DM), capillary volume (VCap) and alveolar volume (VALv) during chronic treatment with carvedilol (C) and bisoprolol (B). *=*p*<0.01 vs. carvedilol; †=*p*<0.02 vs. carvedilol.

Table 3
Cardiopulmonary exercise test data in 53 CHF patients during carvedilol and bisoprolol treatment

	Carvedilol	Bisoprolol	<i>p</i>
Exercise tolerance (min)	9.15±1.39	9.70±1.84	0.002
Peak $\dot{V}O_2$ (mL/min)	1339±417	1400±406	0.05
Peak $\dot{V}O_2$ (mL/min/kg)	17.0±4.6	17.8±4.5	0.04
Peak work-load (W)	105±34	111±36	0.0005
Peak heart rate (b/min)	120±26	119±3.1	NS
Peak O_2p (mL/b)	11.3±3.2	11.9±3.1	NS
\dot{V}_E/VCO_2 slope	30.6±5.3	30.6±5.1	NS
$\dot{V}O_2$ /work slope	9.4±1.5	9.5±1.5	NS

$\dot{V}O_2$ =Oxygen consumption; O_2p =oxygen pulse ($\dot{V}O_2$ /heart rate); \dot{V}_E/VCO_2 =ventilation/carbon dioxide slope; b=beat.

ejection fraction was 37±8% and 38±9%, and mitral insufficiency was 1.3±0.9 and 1.4±0.8, respectively. It was possible to estimate systolic pulmonary pressure in 41 patients; values of 30±10 mm Hg and 30±9 mm Hg were reported for carvedilol and bisoprolol, respectively.

FEV₁ was 91±18% of predicted and 91±19% of predicted (NS) and VC was 94±16% of predicted and 96±19% of predicted (NS), for carvedilol and bisoprolol, respectively. Absolute values of pulmonary function data before and after salbutamol challenge are reported in Table 2. The FEV₁ response to salbutamol was greater with bisoprolol. Results remained similar if data from patients with FEV₁ or VC<80% of predicted were considered separately. DLCO was 82±21% of predicted and 90±20% of predicted with carvedilol and bisoprolol, respectively (*p*<0.01). Absolute values for DLCO, DLCO subcomponents and alveolar volume are reported in Fig. 1. The higher DLCO value with bisoprolol was due to an improvement in DM. Twenty-two subjects had a DLCO value <80% of predicted with either carvedilol (20 cases) or bisoprolol (17 cases). In these subjects, DLCO was 15.9±3.4 mL/min/mm Hg (63±14%) and 17.7±3.1 (72±12%) (*p*<0.02 for both absolute values and %) with carvedilol and bisoprolol, respectively.

The mean cardiopulmonary exercise ramp protocol was 11.4±2.8 W/min. Results are reported in Table 3. The effort intensity during both tests was comparable, with a similar respiratory exchange ratio (Table 3). Data showed a higher

Table 4
Ventilation, tidal volume, respiratory rate and expiratory time during exercise

	Rest ^a	2 min ^a	4 min ^a	6 min ^a	8 min ^b	Peak
\dot{V}_E C (L/min)	11.1±2.6	17.2±3.9	22.9±5.0	32.5±6.8	44.1±9.8	55.0±15.7
\dot{V}_E B (L/min)	10.8±2.8	17.7±4.9	23.3±5.4	32.2±7.8	43.7±11.5	56.4±14.2
Tidal volume C (L)	0.70±0.28	0.90±0.34	1.11±0.41	1.34±0.35	1.59±0.56	1.70±0.56
Tidal volume B (L)	0.68±0.27	0.91±0.31	1.13±0.36	1.30±0.37	1.57±0.43	1.73±0.51
Resp. rate C (b/m)	17±5	20±5	22±5	25±6	29±7	33±7
Resp. rate B (b/m)	17±4	21±6	22±5	26±7	28±6	33±6
Te/Ttot C	0.59±0.09	0.58±0.05	0.56±0.04	0.54±0.03	0.53±0.09	0.53±0.03
Te/Ttot B	0.59±0.06	0.58±0.05	0.57±0.05	0.55±0.03	0.53±0.09	0.53±0.03

C=Carvedilol; B=bisoprolol; \dot{V}_E =ventilation; Resp=respiratory; Te=expiratory time; Ttot=breath time.

^a n=53.

^b n=47.




Fig. 2. Correlation between changes in lung diffusion ($\Delta DLCO$) vs. changes in peak $\dot{V}O_2$ ($\Delta \dot{V}O_{2p}$) between bisoprolol and carvedilol treatment.

exercise performance with bisoprolol. At rest, on the cycloergometer, heart rate was 70±15 and 67±13 b/min (*p*=NS) for carvedilol and bisoprolol, respectively. There was no significant difference in data at anaerobic threshold ($\dot{V}O_2$ =11.3±3.1 mL/min/kg and 11.9±3.7 mL/min/kg; heart rate 97±22 b/min and 92±18 b/min, for carvedilol and bisoprolol, respectively). To assess any possible difference in exercise induced bronchodilation, ventilatory data during exercise were analyzed (Table 4). No differences were identified by our analysis. Changes in peak $\dot{V}O_2$ between carvedilol and bisoprolol treatment were linearly related to changes in DLCO (*R*=0.46, *p*<0.001) (Fig. 2). Considering subjects with DLCO<80% predicted, peak $\dot{V}O_2$ was 15.1±4.4 mL/min/kg and 16.7±5.8 mL/min/kg (*p*<0.01) with carvedilol and bisoprolol, respectively. Also in these 22 patients with low DLCO, changes in peak $\dot{V}O_2$ were related to changes in DLCO (*R*=0.456, *p*<0.05).

As assessed by repeated measurements ANCOVA, no effect of the treatment sequence was observed for any of the study parameters.

4. Discussion

This is the first human study dedicated to understanding the different effects of a β_1 and a β_1 - β_2 blocking agent on lung

function in CHF patients. Results show that chronic treatment with carvedilol (β_1 – β_2 blocker) and bisoprolol (β_1 blocker) has different effects on two aspects of lung function at rest: the response to bronchodilator stimulation and lung diffusion. The difference in response to bronchodilator stimulation did not significantly affect the ventilatory pattern during exercise, but might be a safety issue in case of worsening of pulmonary congestion and the need for acute β -stimulating therapy. The difference between β -blockers on lung diffusion, being selectively related to membrane conductance, is likely due to the changes in active membrane transport which is under β_2 -receptor control. During bisoprolol treatment, exercise capacity was slightly but significantly higher; however, this is unlikely to be of clinical relevance. Exercise performance differences between carvedilol and bisoprolol became more relevant if only patients with impaired DLCO were considered.

Both drugs were up-titrated to what is believed to be the maximal tolerated dose and both reached the same clinical level of β -receptor blockade. Indeed, a 1 to 5 dose relationship between bisoprolol and carvedilol is well known [5]. Furthermore, cardiac function, evaluated by echocardiography, was not different during carvedilol and bisoprolol treatments, nor was heart rate at rest or peak exercise. Similarly, the V_E/VCO_2 slope, an index of ventilatory regulation positively influenced by β -blocking therapy [27], was similar with both drugs. Finally, the doses of both drugs reached in the present study are in the range reported in other clinical studies aimed at CHF treatment with maximal tolerated β -blocker doses [1–3,5]. All these observations suggest a similar degree of β -blockade.

Standard pulmonary function tests were generally normal, a few patients showed, a mild restrictive disease as is usually reported in CHF [11,13]. No difference between carvedilol and bisoprolol was observed. However, the response to inhaled salbutamol, the classic test for bronchodilation, evidenced a superior response in Bisoprolol treated patients. This is important in the case of a need for acute bronchodilation, as during asthma or recrudescence of COPD.

During exercise, expiratory flow limitation occurs in CHF patients, this limits exercise performance [16,17]. It is possible to hypothesize that the different response to salbutamol inhalation has an equivalent in the second part of the exercise, when catecholamine spill-over increases. Indeed, in normal subjects, there is an active bronchodilation during exercise [16,28] and immediately after exercise the maximal flow/volume loop is larger [17]. In the present study, we did not perform a maximal flow/volume manoeuvre during exercise (see study limitations). We limited our analysis to the expiratory time changes during exercise, and observed a similar expiratory time at all levels of exercise with carvedilol and bisoprolol (Table 4), suggesting that major differences in bronchial tone during exercise are absent.

Pulmonary oedema clearance is impaired in animal models of hydrostatic pulmonary oedema and acute lung injury [29,30]. DLCO is reduced by alveolar oedema [31]. It has been known for many years that injection of propranolol reduces

DLCO in experimental animals [32]. However, only recently has it been proved that epithelial β_2 -receptor signals are important for the regulation of alveolar active Na^+ transport when the lung deals with excessive fluids [33]. There is quite a bit of evidence to support this theory: a) alveolar clearance of fluid is reduced by β_2 -receptor loss [33], b) catecholamines stimulate alveolar fluid clearance via activation of β receptors in human [34] and animal lungs [35,36], c) ability to clear instilled fluid is significantly impaired in β_1 and β_1 – β_2 knockout mice [33], d) β stimulating agents prevent pulmonary oedema at high altitude [36] and e) β stimulating agents improve acute lung injury [7].

Lung diffusion depends on DM and capillary volume. Capillary volume is the amount of blood which participates in gas exchange. DM is the specific membrane conductance. DLCO and DM are related to alveolar volume, but alveolar volume was constant during both carvedilol and bisoprolol treatment. We have previously shown that, by acting on active ion transport at the alveolar-capillary membrane level, it is possible to directly interfere with gas diffusion, even in the absence of a haemodynamic effect. Indeed, ACE-inhibitors improve DLCO, but this effect is counteracted by aspirin [37]; while glucose infusion, though not saline infusion, improves alveolar-capillary conductance [38].

We have recently reported that carvedilol, when compared to placebo, reduces DLCO at sea level, reduces arterial pO_2 at rest and during submaximal exercise in normoxic and hypoxic conditions, and reduces exercise capacity at a simulated altitude [39]. We were not able to ascribe these findings to the blockade of alveolar β receptors, because several other causes, specifically carvedilol induced changes in cardiac function and chemoreflex responses, might have been advocated as the cause of these results. In the present study, both drugs were up-titrated to what is believed to be the maximal tolerated dose, so that differences in DLCO and DM are likely the consequence of blockade of β_2 receptors on the epithelial layer of the alveoli. Indeed, particularly in CHF patients, lung fluid homeostasis is a delicate balance between force, which drives fluids into the air space, and the physiological mechanisms which remove fluids from the alveolar surface which includes vectorial trans-epithelial sodium transport which is under β_2 -receptor control [7,40]. The present is the first demonstration, in CHF patients, of an active role for alveolar β receptors, not only in preventing pulmonary oedema [36] but also in regulating alveolar fluid balance. It is not known, however, if the higher level of DLCO and DM observed with bisoprolol implies higher protection against pulmonary oedema [41].

It should be noted that a low DLCO, and specifically a low DM [12], are associated with an unfavourable prognosis in patients with CHF. Bisoprolol increases DLCO when compared to carvedilol in all subjects studied, but particularly in patients with a low DLCO, in other words, in patients with the worst DLCO-related prognosis. It is unknown, however, whether a change in DLCO implies a change in prognosis, and no data are available for a comparison between carvedilol and bisoprolol, in terms of prognosis.

Exercise capacity was significantly higher with bisoprolol when compared to carvedilol. The difference however was quantitatively small and likely clinically mute. Accordingly, the quality of life score was unaffected by the type of β -blocker used. However, peak VO_2 differences were clinically more relevant, on the average of 10%, particularly in subjects with low DLCO. Peak VO_2 increase with bisoprolol was related to DLCO increase, both in the entire population and in patients with DLCO <80% predicted. However, a correlation does not imply a cause–effect relationship. Indeed, other reasons may account for the peak VO_2 differences between bisoprolol and carvedilol, which we observed. In fact, cardiac contractility and chronotropy under exercise is correlated with β -receptor density [42] and bisoprolol, but not carvedilol, leads to an upregulation of down-regulated β_1 receptors. Hence, cardiac contractility reserve under conditions of enhanced sympathetic activity such as exercise, should be larger on bisoprolol treatment and this could explain the higher peak VO_2 we observed with bisoprolol.

This research has a few relevant limitations which should be addressed. First, we have no data on normal subjects. Second, we have not studied CHF patients without β -blockers. This was due to the fact that the majority of CHF patients in our cohort were already on β -blocker therapy, and it was considered unethical to withdraw β -blockers for reasons of research. Third, we have no information about the acute effect of both drugs. Indeed, to achieve a β -blocking effect in heart failure patients, the drug dose needs to be slowly and progressively up-titrated. Fourth, expiratory function during exercise is better characterized by performing a maximal flow/volume manoeuvre than by analyzing, as we did, expiratory time. So we cannot exclude some differences in expiratory flow limitation. However, we decided not to perform maximal flow/volume curves during exercise, because that would have significantly influenced VO_2 and VCO_2 measurements. Fifth, carvedilol also has an alpha-receptor blocking action. At present, there are major doubts about the function and expression of alpha receptors in the lung tissue [43]. However, alpha-blockers should, if anything, have a bronchodilating action which would have improved the respiratory response to the drug. Finally, although there was a higher peak VO_2 with bisoprolol, this does not mean that bisoprolol is superior to carvedilol in CHF, as this is only one aspect of the overall effect of β -blocker therapy. In fact, we did not measure any hard end-points and current published data suggest, if anything, a superiority of carvedilol over the β_1 selective β -blocker metoprolol [44].

Although our study was not designed to investigate differences in clinical benefit between carvedilol and bisoprolol, our findings may implicate that bisoprolol could be preferred to carvedilol, as a first line therapy, in patients presenting with a low DLCO.

In conclusion, in terms of DLCO, response to salbutamol challenge and exercise capacity, this study shows a superior effect of bisoprolol over carvedilol in CHF patients. DLCO

and exercise capacity differences are more relevant in patients with a low DLCO.

References

- [1] Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. *N Engl J Med* 1996;334:1349–55.
- [2] Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. *Circulation* 1996;94:2800–6.
- [3] CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. *Lancet* 1999;353:9–13.
- [4] Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. *Circulation* 2005;112:2426–35.
- [5] Bristow MR, Linas S, Port JD. Drugs in the treatment of heart failure. In: Zipes Douglas P, Libby Peter, Bonow Robert O, Braunwald Eugene, editors. *Braunwald's heart disease: a textbook of cardiovascular medicine* 7th ed. ; 2005. p. 569–601.
- [6] Carstairs JR, Nimmo AJ, Barnes PJ. Autoradiographic visualization of beta-adrenoceptors subtypes in human lung. *Am Rev Respir Dis* 1985;132:541–7.
- [7] Mutlu GM, Koch WJ, Factor P. Alveolar epithelial α_2 -adrenergic receptors. Their role in regulation of alveolar active sodium transport. *Am J Respir Crit Care Med* 2004;170:1270–5.
- [8] Spina D, Rigby PJ, Paterson JW, Goldie RG. Autoradiographic localization of beta-adrenoceptors in asthmatic human lung. *Am Rev Respir Dis* 1989;140:1410–5.
- [9] Crone C, Saumon G, Basset G. News from the alveoli. *News Physiol Sci* 1990;5:50–3.
- [10] Puri S, Dutka DP, Baker BL, Hughes JMB, Cleland JGF. Acute saline infusion reduces alveolar-capillary membrane conductance and increases airflow obstruction in patients with left ventricular dysfunction. *Circulation* 1999;99:1190–6.
- [11] Naum CC, Scieurba C, Rogers RM. Pulmonary function abnormalities in chronic severe cardiomyopathy preceding cardiac transplantation. *Am Rev Respir Dis* 1992;145:1334–8.
- [12] Guazzi M, Pontone G, Brambilla R, Agostoni P, Reina G. Alveolar-capillary membrane gas conductance: a novel prognostic indicator in chronic heart failure. *Eur Heart J* 2002;23:467–76.
- [13] Wasserman K, Zhang Y, Gitt A, et al. Lung function and exercise gas exchange in chronic heart failure. *Circulation* 1997;96:2221–7.
- [14] Puri S, Baker BL, Dutka DP, Oakley CM, Hughes JMB, Cleland JGF. Reduced alveolar-capillary membrane diffusing capacity in chronic heart failure. Its pathophysiological relevance and relationship to exercise performance. *Circulation* 1995;91:2769–74.
- [15] Cabanes LR, Weber SN, Matran R, et al. Bronchial hyperresponsiveness to methacholine in patients with impaired left ventricular function. *N Engl J Med* 1989;320:1317–22.
- [16] Johnson BD, Beck KC, Olson LJ, et al. Ventilatory constraints during exercise in patients with chronic heart failure. *Chest* 2000;117:321–32.
- [17] Agostoni PG, Pellegrino R, Conca C, Rodarte JR, Brusasco V. Exercise hyperpnea in chronic heart failure: relation to lung stiffness and expiratory flow limitation. *J Appl Physiol* 2002;92:1409–16.
- [18] Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota living with heart failure questionnaire as a measure of therapeutic response to enalapril or placebo. *Am J Cardiol* 1993;71:1106–7.
- [19] Feigenbaum H, Armstrong WF, Ryan T. Hemodynamics. In Feigenbaum's *Echocardiography*, sixth edition. Ed. Lippincott Williams and Wilkins 2005; p. 214–246.
- [20] American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. *Am Rev Respir Dis* 1991;144:1202–18.

- [21] Quanjer PH, Tammeling GJ, Cotes JE. Standardized lung function testing. *Eur Respir J* 1993;6:1–99.
- [22] Huang YC, Helms MJ, MacIntyre NR. Normal values for single exhalation diffusing capacity and pulmonary capillary blood flow in sitting, supine position, and during mild exercise. *Chest* 1994;105:501–8.
- [23] Roughton FJW, Forster RE. Relative importance of diffusion and chemical reaction rates in determining rate of exchange of gases in the human lung, with special reference to true diffusing capacity of pulmonary membrane and volume of blood in the lung capillaries. *J Appl Physiol* 1957;2:290–302.
- [24] Ramage JE, Coleman RE, MacIntyre NR. Rest and exercise output and diffusive capacity assessed by a single slow exhalation of methane, acetylene, and carbon monoxide. *Chest* 1987;92:44–50.
- [25] Agostoni PG, Bianchi M, Moraschi A, et al. Work-rate affects cardiopulmonary exercise test results in heart failure. *Eur J Heart Fail* 2005;7:498–504.
- [26] Beaver WL, Wasserman K, Whipp BJ. A new method for detecting the anaerobic threshold by gas exchange. *J Appl Physiol* 1986;60:2020–7.
- [27] Agostoni PG, Guazzi M, Bussotti M, De Vita S, Palermo P. Carvedilol reduces the inappropriate increase of ventilation during exercise in heart failure. *Chest* 2002;122:2062–7.
- [28] Pellegrino R, Villosio C, Milanese U, Garelli G, Rodarte JR, Brusasaco V. Regional expiratory flow limitation studied with Technegas in asthma. *J Appl Physiol* 2001;91:2190–8.
- [29] Azzam ZS, Dumasius V, Saldias FJ, Adir Y, Sznajder JI, Factor P. Na, K-ATPase overexpression improves alveolar fluid clearance in a rat model of elevated left atrial pressure. *Circulation* 2002;105:497–501.
- [30] Olivera W, Ridge K, Wood LD, Sznajder JI. Active sodium transport and alveolar epithelial Na–K-ATPase increase during subacute hyperoxia in rats. *Am J Physiol* 1994;266:L577–84.
- [31] Agostoni PG, Cattadori G, Bianchi M, Wasserman K. Exercise-induced pulmonary edema in heart failure. *Circulation* 2003;108:2666–71.
- [32] Brashear RE, Ross JC. Effect of dipirydamole and propranolol on pulmonary diffusing capacity during rest and exercise. *Am Rev Respir Dis* 1968;98:1048–51.
- [33] Mutlu GM, Dumasius V, Burhop J, et al. Upregulation of alveolar epithelial active Na⁺ transport is dependent on β 2-adrenergic receptor signalling. *Circ Res* 2004;94:1091–100.
- [34] Sakuma T, Okaniwa G, Nakada T, Nishimura T, Fujimura S, Matthay MA. Alveolar fluid clearance in the resected human lung. *Am J Respir Crit Care Med* 1994;150:305–10.
- [35] Berthiaume Y, Staub NC, Matthay MA. Beta-adrenergic agonists increase lung liquid clearance in anesthetized sheep. *J Clin Invest* 1987;79:335–43.
- [36] Sartori C, Duplain H, Lepori M, et al. Salmeterol for the prevention of high-altitude pulmonary edema. *N Engl J Med* 2002;346:1631–6.
- [37] Guazzi M, Marenzi G, Alimento M, Contini M, Agostoni PG. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. *Circulation* 1997;95:1930–6.
- [38] Guazzi M, Agostoni PG, Bussotti M, Guazzi MD. Impeded alveolar-capillary gas transfer with saline infusion in heart failure. *Hypertension* 1999;34:1202–7.
- [39] Agostoni PG, Contini M, Magini A, et al. Carvedilol reduces exercise-induced hyperventilation: a benefit in normoxia and a problem with hypoxia. *Eur J Heart Fail* 2006;8:729–35.
- [40] Mutlu GM, Sznajder JI. Mechanism of pulmonary edema clearance. *Am J Physiol Lung Cell Mol Physiol* 2005;289:L685–95.
- [41] Guazzi M, Agostoni PG, Guazzi MD. Modulation of alveolar-capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by losartan, in chronic heart failure. *J Am Coll Cardiol* 2001;37:398–406.
- [42] White M, Yanowitz F, Gilbert EM, et al. Role of beta-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy. *Am J Cardiol* 1995;76:1271–6.
- [43] Novakova M, Myslivecek J. Identification of all alpha1-adrenoceptor subtypes in rat lung. *Gen Physiol Biophys* 2005;25:349–53.
- [44] Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with CHF in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. *Lancet* 2003;362:7–13.